Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Apr;102(4):926-30.
doi: 10.1111/j.1476-5381.1991.tb12278.x.

Characterization of Gaddum's substance R

Affiliations

Characterization of Gaddum's substance R

G J Douglas et al. Br J Pharmacol. 1991 Apr.

Abstract

1. When the isolated small intestine of the rat is perfused via the mesenteric artery, an oxytocic principle (Gaddum's substance R) is released which is detectable in the perfusate after 30 min and is present in samples collected 8 h later. 2. The oxytocic activity of substance R is lost after boiling but is unaffected by treatment with thioglycolate. Furthermore, atropine, methysergide and indomethacin failed to antagonize uterine contractions to substance R. 3. Neither substance R nor urinary kallikrein alone induce a contraction of the guinea-pig isolated ileum. However, in the presence of kininogen both substance R and urinary kallikrein produce a slow and prolonged contraction of the guinea-pig ileum. 4. The oxytocic and kininogenase properties of both substance R and urinary kallikrein are inhibited by Trasylol. 5. Soy bean trypsin inhibitor (SBTI) selectively inhibited both the oxytocic and the kininogenase activities of substance R but not those of urinary kallikrein. 6. Gel filtration of substance R resolved a single peak of oxytocic activity with an estimated molecular weight of 40 kDa. 7. We conclude that substance R is a kininogenase enzyme which may be distinguished from plasma kallikrein by its molecular weight and from urinary kallikrein by its susceptibility to SBTI. The exact nature of this enzyme remains to be elucidated.

PubMed Disclaimer

Similar articles

References

    1. Br J Pharmacol Chemother. 1953 Sep;8(3):321-6 - PubMed
    1. Br J Pharmacol Chemother. 1968 Mar;32(3):453-65 - PubMed
    1. J Biol Chem. 1951 Nov;193(1):265-75 - PubMed
    1. J Pharmacol Exp Ther. 1989 May;249(2):470-5 - PubMed
    1. Adv Exp Med Biol. 1986;198 Pt A:11-7 - PubMed

MeSH terms

LinkOut - more resources